Human calcitonin

DB06773

biotech approved investigational

Deskripsi

Calcitonin was first discovered in isolated parathyroid tissue as a substance with a serum-calcium-lowering effect.A32099 It is constituted as a 32-amino acid single chain polypeptide structure that gets secreted as a regulatory agent in calcium-phosphorus metabolism.A32098 It is used as an alternative for people developing antibodies against salmon calcitonin.A32100

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Intravenous administration of human calcitonin presents a half-life in the range of 10.2-37.8 min.[A32110]
Volume Distribusi -
Klirens (Clearance) The metabolic clearance rate is in the range of 6-9 ml/min.kg while the secretion rate is 59 ng/dl.kg for men and 22 ng/dl.kg for women.[A32111] The total renal clearance of human calcitonin is 1.96 ml/min. The renal clearance exceeds the glomerular filtration rate which indicates a filtration-independent removal.[A32112]

Absorpsi

The human calcitonin tends to aggregate irreversibly forming amyloid fibrils. This property compromises the bioavailability and therapeutic activity of exogenous human calcitonin.A32107 When human calcitonin reaches the intestine, by intracolonic administration, it is absorbed within minutes and it is distributed intact in plasma. The level of absorption is low and the bioavailability can range from 0.01-2.7%.A32109

Metabolisme

The kidneys account for two-thirds of the metabolism of calcitonin and generate low molecular weight forms. At a subcellular level, it has been observed the metabolic activity of N-acetyl-beta-glucosaminidase, alanyl aminopeptidase, and phosphoglucomutase.A32112

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

13 Data
Pamidronic acid The risk or severity of hypocalcemia can be increased when Human calcitonin is combined with Pamidronic acid.
Zoledronic acid The risk or severity of hypocalcemia can be increased when Human calcitonin is combined with Zoledronic acid.
Alendronic acid The risk or severity of hypocalcemia can be increased when Human calcitonin is combined with Alendronic acid.
Ibandronate The risk or severity of hypocalcemia can be increased when Human calcitonin is combined with Ibandronate.
Clodronic acid The risk or severity of hypocalcemia can be increased when Human calcitonin is combined with Clodronic acid.
Risedronic acid The risk or severity of hypocalcemia can be increased when Human calcitonin is combined with Risedronic acid.
Etidronic acid The risk or severity of hypocalcemia can be increased when Human calcitonin is combined with Etidronic acid.
Tiludronic acid The risk or severity of hypocalcemia can be increased when Human calcitonin is combined with Tiludronic acid.
Incadronic acid The risk or severity of hypocalcemia can be increased when Human calcitonin is combined with Incadronic acid.
Lithium citrate Human calcitonin may increase the excretion rate of Lithium citrate which could result in a lower serum level and potentially a reduction in efficacy.
Lithium carbonate Human calcitonin may increase the excretion rate of Lithium carbonate which could result in a lower serum level and potentially a reduction in efficacy.
Lithium hydroxide Human calcitonin may increase the excretion rate of Lithium hydroxide which could result in a lower serum level and potentially a reduction in efficacy.
Magnesium The serum concentration of Magnesium can be increased when it is combined with Human calcitonin.

Target Protein

Alpha-actinin-1 ACTN1

Referensi & Sumber

Artikel (PubMed)
  • PMID: 8454613
    Arvinte T, Drake AF: Comparative study of human and salmon calcitonin secondary structure in solutions with low dielectric constants. J Biol Chem. 1993 Mar 25;268(9):6408-14.
  • PMID: 5563336
    Authors unspecified: Clinical applications of calcitonin. Can Med Assoc J. 1971 Aug 7;105(3):238-9.
  • PMID: 1164607
    Authors unspecified: Editorial: Paget's disease and calcitonin. Br Med J. 1975 Aug 30;3(5982):505-6.
  • PMID: 28255281
    Alonso N, Calero-Paniagua I, Del Pino-Montes J: Clinical and Genetic Advances in Paget's Disease of Bone: a Review. Clin Rev Bone Miner Metab. 2017;15(1):37-48. doi: 10.1007/s12018-016-9226-0. Epub 2016 Dec 19.
  • PMID: 16006528
    Fowler SB, Poon S, Muff R, Chiti F, Dobson CM, Zurdo J: Rational design of aggregation-resistant bioactive peptides: reengineering human calcitonin. Proc Natl Acad Sci U S A. 2005 Jul 19;102(29):10105-10. doi: 10.1073/pnas.0501215102. Epub 2005 Jul 8.
  • PMID: 15741694
    Yamamoto Y, Noguchi T, Takahashi N: Effects of calcitonin on osteoclast. Clin Calcium. 2005 Mar;15(3):147-51. doi: CliCa0503467471.
  • PMID: 1483490
    Beglinger C, Born W, Muff R, Drewe J, Dreyfuss JL, Bock A, Mackay M, Fischer JA: Intracolonic bioavailability of human calcitonin in man. Eur J Clin Pharmacol. 1992;43(5):527-31.
  • PMID: 1335402
    Antonin KH, Saano V, Bieck P, Hastewell J, Fox R, Lowe P, Mackay M: Colonic absorption of human calcitonin in man. Clin Sci (Lond). 1992 Nov;83(5):627-31.
Menampilkan 8 dari 10 artikel.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul